- A 55-year-old man with a history of chronic alcohol use disorder and poor nutrition is hospitalized and started on TMP-SMX. Which of the following adverse effects is this patient at a particularly high risk of developing due to his underlying condition?
Answer: Megaloblastic anemia
Patients with chronic alcohol use disorder and poor nutrition are often folate deficient. Trimethoprim inhibits dihydrofolate reductase, the enzyme that converts dihydrofolate to the active tetrahydrofolate. In a patient with pre-existing folate deficiency, this inhibition can precipitate or worsen megaloblastic anemia, which is characterized by impaired DNA synthesis and the presence of large, immature red blood cells.
- A patient with HIV and a CD4 count of 80 cells/μL is receiving TMP-SMX as prophylaxis for Pneumocystis jirovecii pneumonia (PJP). The efficacy of TMP-SMX against this organism is based on the fact that Pneumocystis jirovecii:
Answer: is a fungus that, unlike most other fungi, must synthesize its own folate de novo.
Pneumocystis jirovecii is an atypical fungus. While most fungi are not susceptible to sulfonamides, P. jirovecii is an exception because it cannot absorb folate from its environment (the human host) and possesses the enzymes for de novo folate synthesis, including dihydropteroate synthase and dihydrofolate reductase. Therefore, its folate synthesis pathway is susceptible to inhibition by TMP-SMX, just like susceptible bacteria.
- The combination of trimethoprim and sulfamethoxazole demonstrates significant synergy and is often bactericidal, whereas either agent alone is typically bacteriostatic. This synergy is best explained by which of the following principles?
Answer: Inhibition of two sequential steps in a critical bacterial metabolic pathway.
The synergistic effect of TMP-SMX is a classic example of sequential blockade. Sulfamethoxazole inhibits dihydropteroate synthase, an early step in the bacterial folate synthesis pathway. Trimethoprim inhibits dihydrofolate reductase, a subsequent step in the same pathway. By blocking the pathway at two different points, the combination produces a much greater inhibition of tetrahydrofolate synthesis than either drug alone, often resulting in a bactericidal effect.
- The structural similarity between sulfamethoxazole and para-aminobenzoic acid (PABA) is fundamental to the drug's mechanism of action. In bacteria, PABA is an essential precursor for the synthesis of which of the following molecules?
Answer: Dihydropteroic acid
In the bacterial de novo folate synthesis pathway, the enzyme dihydropteroate synthase catalyzes the condensation of a pteridine precursor with para-aminobenzoic acid (PABA) to form dihydropteroic acid. This is the specific step inhibited by sulfonamides. While the end products of folate metabolism are used for purine and pyrimidine (specifically thymidine) synthesis, PABA is not a direct precursor for their ring structures.
- Administration of a sulfonamide to a neonate with hyperbilirubinemia is contraindicated due to the high risk of kernicterus. What is the direct mechanism by which the sulfonamide precipitates this condition?
Answer: Displacement of bilirubin from its binding sites on serum albumin.
Sulfonamides are highly protein-bound and can compete with and displace unconjugated bilirubin from its binding sites on serum albumin. This increases the concentration of free, unbound bilirubin in the plasma. In neonates, whose blood-brain barrier is immature, this free bilirubin can cross into the central nervous system and deposit in the basal ganglia, causing bilirubin-induced neurologic dysfunction (kernicterus).
- A 62-year-old woman with rheumatoid arthritis, well-controlled on weekly low-dose methotrexate, develops a UTI and is prescribed TMP-SMX. Shortly after, she develops severe stomatitis, pancytopenia, and elevated liver enzymes. This presentation of methotrexate toxicity is most likely a result of:
Answer: Sulfamethoxazole displacing methotrexate from albumin and trimethoprim inhibiting its renal clearance.
When you encounter drug interaction questions involving methotrexate, focus on the dual mechanisms that can dramatically increase its toxicity: protein displacement and renal clearance inhibition.
Methotrexate normally circulates bound to albumin and is cleared renally through active secretion. TMP-SMX creates a dangerous combination by attacking both these protective mechanisms simultaneously. Sulfamethoxazole displaces methotrexate from its albumin binding sites, suddenly increasing free (active) drug levels in the blood. Meanwhile, trimethoprim competes with methotrexate for the same renal transporters, blocking its elimination. This dual hit causes methotrexate levels to skyrocket, leading to the classic toxicity triad: stomatitis (mucosal damage), pancytopenia (bone marrow suppression), and hepatotoxicity.
Option B is incorrect because this isn't about direct synergistic toxicity—it's a pharmacokinetic interaction that increases methotrexate exposure. Option C misses the mark; while methotrexate does affect folate metabolism, the acute toxicity here results from increased drug levels, not unmasked folate deficiency. Option D incorrectly suggests a hypersensitivity mechanism when this is clearly dose-related toxicity.
The key study point: memorize that TMP-SMX is contraindicated with methotrexate due to this dual pharmacokinetic interaction. On pharmacology exams, when you see methotrexate toxicity scenarios, immediately consider what drugs might displace it from protein binding (sulfonamides, NSAIDs) or block its renal elimination (trimethoprim, probenecid). This interaction is potentially fatal and represents a high-yield exam topic.
- Trimethoprim exhibits selective toxicity against bacterial dihydrofolate reductase (DHFR) over the human equivalent. This selectivity is the basis for its therapeutic use. The affinity of trimethoprim for bacterial DHFR is approximately how many times greater than its affinity for human DHFR?
Answer: 50,000 to 100,000 times
The basis for trimethoprim's selective toxicity is its remarkably higher affinity for the bacterial dihydrofolate reductase enzyme compared to the human enzyme. Trimethoprim binds to bacterial DHFR approximately 50,000 to 100,000 times more tightly than it binds to mammalian DHFR. This vast difference in affinity allows for effective inhibition of the bacterial enzyme at concentrations that have minimal effect on the host's folate metabolism, although toxicity can still occur at high doses or in susceptible individuals (e.g., folate deficient).
- A patient being treated with high-dose TMP-SMX develops acute kidney injury. Urinalysis reveals needle-shaped crystals. This complication is primarily due to the precipitation of which component, and what intervention is most likely to mitigate this risk?
Answer: Sulfamethoxazole and its metabolites; ensuring adequate hydration.
Sulfonamides, particularly their acetylated metabolites, have low solubility in acidic urine and can precipitate to form crystals (crystalluria). This can lead to tubular obstruction and acute kidney injury. The primary component responsible is sulfamethoxazole. The most important preventive measure is to maintain adequate hydration and high urine output to keep the drug and its metabolites diluted.
- A 34-year-old patient is prescribed TMP-SMX for a skin and soft tissue infection. Ten days later, she develops fever, sore throat, and a rapidly spreading dusky rash with blister formation and extensive mucosal involvement. A skin biopsy would most likely show which of the following findings?
Answer: Full-thickness necrosis of the epidermis with dermoepidermal separation.
The clinical presentation is highly suggestive of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), a severe mucocutaneous adverse reaction commonly associated with sulfonamides. The characteristic histopathological finding in SJS/TEN is full-thickness necrosis (apoptosis) of the epidermis, leading to separation from the underlying dermis. The other options describe different dermatological conditions: (A) bullous pemphigoid, (C) pemphigus vulgaris, and (D) eczematous dermatitis.
- A patient develops a morbilliform rash on day 8 of TMP-SMX therapy. The rash is non-pruritic, non-painful, and there is no mucosal involvement or other systemic symptoms. Which of the following is the most important feature distinguishing this reaction from the more severe Stevens-Johnson syndrome (SJS)?
Answer: The absence of mucosal erosions and epidermal detachment.
The key features that distinguish a simple drug exanthem (morbilliform rash) from life-threatening conditions like Stevens-Johnson syndrome (SJS) are the presence of severe signs. SJS is characterized by painful, dusky, or purpuric macules that lead to epidermal detachment (positive Nikolsky sign) and, critically, involvement of at least two mucosal surfaces (e.g., oral, ocular, genital). The absence of these features is the most important differentiating factor.
- A 25-year-old man of Mediterranean descent is treated with TMP-SMX. He develops fatigue, jaundice, and dark urine. A complete blood count reveals anemia, and a peripheral smear shows bite cells and Heinz bodies. This reaction is most likely due to an inherited deficiency that impairs the regeneration of which of the following?
Answer: Reduced glutathione (GSH)
When you see a patient of Mediterranean descent developing hemolytic anemia after taking TMP-SMX, with bite cells and Heinz bodies on peripheral smear, think glucose-6-phosphate dehydrogenase (G6PD) deficiency. This X-linked disorder is common in Mediterranean populations and creates vulnerability to oxidative stress from certain medications.
G6PD is the rate-limiting enzyme in the pentose phosphate pathway, which generates NADPH. Red blood cells rely heavily on NADPH to regenerate reduced glutathione (GSH) from its oxidized form (GSSG). GSH is the cell's primary antioxidant defense system. When G6PD is deficient, cells cannot maintain adequate GSH levels during oxidative stress, leading to hemolysis. TMP-SMX is a classic oxidizing drug that triggers this reaction.
Let's examine why the other options don't fit: (A) Tetrahydrofolate deficiency would cause megaloblastic anemia, not acute hemolytic anemia with bite cells and Heinz bodies. (B) Pyruvate kinase deficiency causes chronic hemolytic anemia but isn't triggered by specific medications and doesn't produce this characteristic smear pattern. (C) Methemoglobin reductase deficiency causes methemoglobinemia with cyanosis, not hemolytic anemia.
The correct answer is (D) because G6PD deficiency specifically impairs the cell's ability to regenerate reduced glutathione during oxidative stress.
Study tip: Remember the classic triad for G6PD deficiency: Mediterranean/African/Middle Eastern ancestry + oxidizing drug exposure + acute hemolytic anemia with bite cells. Common trigger drugs include sulfonamides, antimalarials, and nitrofurantoin.
- An 80-year-old male stabilized on warfarin for atrial fibrillation is prescribed a 10-day course of TMP-SMX for prostatitis. Three days into therapy, his INR is found to be 8.5 (therapeutic range 2.0-3.0). This significant interaction is primarily caused by which two mechanisms?
Answer: Displacement of warfarin from albumin and inhibition of CYP2C9.
TMP-SMX potentiates the effect of warfarin through two major mechanisms. First, sulfamethoxazole is highly protein-bound and displaces warfarin from its binding sites on albumin, increasing the free, active fraction of warfarin. Second, both trimethoprim and sulfamethoxazole are inhibitors of the cytochrome P450 enzyme CYP2C9, which is the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. The combination of these effects leads to a rapid and significant increase in INR.
- A 72-year-old male with a history of hypertension controlled with lisinopril is treated with trimethoprim-sulfamethoxazole (TMP-SMX) for a urinary tract infection. On day 5 of treatment, he presents to the emergency department with muscle weakness and palpitations. An ECG shows peaked T waves. This clinical presentation is most likely due to trimethoprim-mediated inhibition of which of the following?
Answer: Epithelial sodium channels in the collecting duct.
The patient's symptoms (muscle weakness, palpitations) and ECG finding (peaked T waves) are characteristic of hyperkalemia. Trimethoprim, a component of TMP-SMX, has a structure similar to the potassium-sparing diuretic amiloride. It directly inhibits the epithelial sodium channel (ENaC) in the collecting duct of the nephron. This inhibition reduces sodium reabsorption and consequently decreases potassium secretion, leading to hyperkalemia, especially in patients with renal impairment or those taking other drugs that increase potassium, such as ACE inhibitors (lisinopril).
- A 68-year-old male with chronic kidney disease (eGFR 25 mL/min) is being considered for TMP-SMX therapy. In addition to dose adjustment, which two adverse effects require particularly close monitoring in this patient due to his underlying condition?
Answer: Hyperkalemia and crystalluria
When approaching TMP-SMX therapy in patients with chronic kidney disease, you need to consider how reduced renal function affects both drug clearance and the patient's susceptibility to specific adverse effects.
TMP-SMX poses two particular risks in CKD patients. First, trimethoprim blocks epithelial sodium channels in the distal nephron, reducing potassium excretion and potentially causing hyperkalemia - especially dangerous when baseline kidney function is already compromised. Second, sulfamethoxazole can precipitate in acidic urine when concentrated due to poor renal clearance, leading to crystalluria and potential further kidney damage.
Looking at the incorrect options: Option B (Stevens-Johnson syndrome and photosensitivity) represents serious but rare adverse effects that aren't specifically heightened by CKD - these are idiosyncratic reactions that occur regardless of kidney function. Option C (megaloblastic anemia and kernicterus) contains one effect (megaloblastic anemia from folate antagonism) that could theoretically occur but isn't CKD-specific, while kernicterus only affects neonates with immature blood-brain barriers. Option D (hemolytic anemia and agranulocytosis) describes hematologic toxicities that, while serious, aren't particularly enhanced by reduced kidney function.
The correct answer is A because both hyperkalemia and crystalluria are directly worsened by the patient's underlying CKD.
Study tip: When evaluating drug safety in organ dysfunction, always ask: "How does the impaired organ affect drug clearance, and which adverse effects would be amplified by the underlying pathophysiology?" This approach helps you identify the most clinically relevant monitoring priorities.
- While TMP-SMX is often considered bactericidal, its clinical efficacy can depend on the host's immune status. In which of the following patient populations would the bacteriostatic nature of the individual components be of greatest concern, potentially leading to treatment failure?
Answer: A neutropenic patient undergoing chemotherapy for acute myeloid leukemia.
Bacteriostatic agents inhibit bacterial growth but rely on a competent host immune system (e.g., neutrophils, macrophages) to clear the non-replicating bacteria. In a patient who is profoundly neutropenic due to chemotherapy, the immune system is unable to perform this function. Therefore, infections in severely immunocompromised hosts ideally require bactericidal agents that can kill the bacteria without assistance from host defenses. The reliance on host immunity is a key limitation of bacteriostatic drugs in this population.
- A strain of Escherichia coli exhibits resistance to sulfamethoxazole. Genetic analysis reveals a mutation that leads to a significant overproduction of a specific endogenous molecule, allowing the bacterium to bypass the drug's inhibitory effect. Which of the following molecules is most likely overproduced by this resistant strain?
Answer: Para-aminobenzoic acid (PABA)
Sulfonamides, like sulfamethoxazole, act as competitive inhibitors of the enzyme dihydropteroate synthase. They compete with the natural substrate, para-aminobenzoic acid (PABA). In competitive inhibition, the effect of the inhibitor can be overcome by increasing the concentration of the substrate. Therefore, a bacterial strain that overproduces PABA would be resistant to the effects of sulfamethoxazole.
- An elderly patient with type 2 diabetes, managed with glipizide, is given TMP-SMX. The patient is brought to the clinic with confusion and diaphoresis. A fingerstick glucose is 45 mg/dL. This adverse event is most likely caused by sulfamethoxazole's ability to:
Answer: displace glipizide from plasma albumin and inhibit its metabolism.
Sulfamethoxazole can cause severe hypoglycemia in patients taking sulfonylureas like glipizide. There are two main mechanisms: 1) Sulfonamides are highly protein-bound and can displace sulfonylureas from albumin, increasing the concentration of free, active drug. 2) Sulfonamides can inhibit the CYP2C9 enzyme, which is responsible for the metabolism of many sulfonylureas, thereby prolonging their half-life and duration of action. The combined effect significantly potentiates the glucose-lowering action of the sulfonylurea.
- Sulfonamides are selectively toxic to bacteria because mammalian cells are not susceptible to their primary mechanism of action. What is the fundamental biological difference that accounts for this selectivity?
Answer: Mammalian cells lack the enzymes for de novo synthesis of folic acid and must utilize dietary folate.
The basis for the selective toxicity of sulfonamides is a fundamental difference in metabolism. Bacteria must synthesize their own folic acid from PABA de novo. Sulfonamides inhibit this pathway. In contrast, mammalian cells cannot synthesize folic acid and have evolved to rely on an uptake system to acquire pre-formed folate (as folic acid) from the diet. Since humans lack the targeted pathway (de novo synthesis via dihydropteroate synthase), sulfonamides have no effect on human folate metabolism.
- A patient is counseled to use sunscreen and protective clothing while taking TMP-SMX. This precaution is necessary to mitigate the risk of a phototoxic reaction, which is mechanistically characterized by:
Answer: UV light-induced conversion of the drug into a reactive metabolite that causes direct cellular damage.
When you encounter questions about drug-induced photosensitivity reactions, focus on understanding the two main mechanisms: phototoxic versus photoallergic reactions. TMP-SMX causes phototoxic reactions, which involve direct chemical damage rather than immune system activation.
Phototoxic reactions occur when UV light provides the energy needed to convert an otherwise harmless drug molecule into a reactive species that directly damages cellular components like DNA, proteins, and lipids. This is exactly what happens with TMP-SMX - the drug absorbs UV radiation and becomes chemically activated, leading to immediate cellular injury. Answer D correctly describes this direct photochemical mechanism.
Let's examine why the other options are incorrect. Choice A describes a delayed-type hypersensitivity reaction, which characterizes photoallergic reactions (not phototoxic ones) and requires prior sensitization and immune memory. Choice B suggests impaired melanin synthesis, but TMP-SMX doesn't interfere with melanocyte function - the photosensitivity occurs regardless of baseline pigmentation. Choice C describes immune complex deposition, which is a Type III hypersensitivity mechanism unrelated to drug photosensitivity reactions.
The key distinction to remember is that phototoxic reactions are immediate, dose-dependent chemical events that can occur on first exposure, while photoallergic reactions are delayed immune responses requiring prior sensitization. For pharmacology exams, when you see photosensitizing drugs like TMP-SMX, fluoroquinolones, or tetracyclines, think "UV + drug = reactive metabolite = direct cellular damage" rather than immune-mediated mechanisms.
